China FDA approves TaiGen Biotech pneumonia-focused Taigexyn antibiotic

Taipei-based TaiGen Biotech has won approval from the China FDA to sell its new antibiotic, Taigexyn (nemonoxacin), that successfully cleared a Phase III trial late last year in Taiwan and mainland China to treat pneumonia.

Pharma Asia June 15, 2016